title: Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.
abstract: BACKGROUND
  High-dose chemotherapy with autologous stem-cell transplantation is used increasingly in the treatment of poor-prognosis primary breast cancer. Because these patients may be cured with standard multimodality therapy, it is important to address both the efficacy of transplantation, and its effect on the delivery of standard treatments including local radiation therapy.
  
  
  METHODS
  Patients with high risk primary breast cancer were treated with high-dose cyclophosphamide and thiotepa and stem-cell transplant following surgery and conventional-dose adjuvant chemotherapy. Outcome, including sites of failure and delivery of local radiation therapy, was assessed for 103 patients.
  
  
  RESULTS
  Overall and disease-free survival rates at 18 months were 83% (+/- 4%) and 77% (+/- 4%) respectively. Twenty patients (19.4%) received radiation therapy prior to transplant. Of the remaining 83, 77 received radiation therapy after transplant. Overall, 5 (19.2%) of 26 first sites of recurrence were local alone. For patients receiving radiation prior to transplant, 3 of 7 (43%, 95% CI: 6%-80%) sites of first recurrence were local, while 2 of 19 (10.5%, 95% CI: 0%-24.5%) sites of first recurrence were local alone in patients receiving post-transplant radiation or no radiation.
  
  
  CONCLUSIONS
  Transplantation does not appear to significantly compromise the delivery or outcome of local radiation therapy for primary breast cancer.
authors.affiliation: Bone Marrow and Stem-Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, USA.
authors.forename: H C
authors.initials: HC
authors.lastname: Moore
authors.forename: R
authors.initials: R
authors.lastname: Mick
authors.forename: L J
authors.initials: LJ
authors.lastname: Solin
authors.forename: C
authors.initials: C
authors.lastname: Sickles
authors.forename: P A
authors.initials: PA
authors.lastname: Mangan
authors.forename: S M
authors.initials: SM
authors.lastname: Luger
authors.forename: K R
authors.initials: KR
authors.lastname: Fox
authors.forename: L M
authors.initials: LM
authors.lastname: Schuchter
authors.forename: E
authors.initials: E
authors.lastname: Loh
authors.forename: D L
authors.initials: DL
authors.lastname: Porter
authors.forename: S
authors.initials: S
authors.lastname: Schuster
authors.forename: G P
authors.initials: GP
authors.lastname: Buzby
authors.forename: E
authors.initials: E
authors.lastname: Glatstein
authors.forename: L E
authors.initials: LE
authors.lastname: Silberstein
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012720:Severity of Illness Index; D016019:Survival Analysis; D013852:Thiotepa / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D013852:Thiotepa